ASCO Annual Meeting 2025
About the event
The American Society of Clinical Oncology Annual Meeting is the world’s leading forum for oncology research and clinical practice. With more than 40,000 attendees across five days, ASCO brings together oncologists, translational researchers, clinical trialists and drug developers from across the globe to present and discuss the latest advances in cancer treatment and drug development.
The 2025 meeting continues a particular focus on early-phase trial design, novel endpoint strategies and the evolving role of imaging in Phase I and II programs — areas that sit directly at the intersection of what Fidēs was built to support.
Fidēs at ASCO 2025
Fidēs Imaging
What we are doing at ASCO this year
The Fidēs team will be present throughout the meeting and available for conversations about your oncology imaging program. We are attending a number of scientific sessions focused on early-phase oncology imaging and endpoint strategy, and will be presenting a poster on additive endpoint design in Phase I solid tumour programs.
- Poster presentation — additive imaging endpoint design in Phase I oncology (see session details below)
- Available for meetings throughout the conference — contact us in advance to arrange a time
- Attending scientific sessions on imaging biomarkers, novel endpoints and Phase I trial design
If you are attending ASCO and would like to speak with us about your imaging program — whether it is in development, actively running, or at the design stage — we would be happy to find time for a conversation. Get in touch via the Contact Us page and mention ASCO 2025 in your message.
Team attending
Roughan Sheedy
Managing Director
Dr Alex Menys
CSO
Poster session
The Fidēs science team will be presenting the following poster at ASCO 2025. Details of session timing and board number will be confirmed closer to the event.
Poster title
Motion-Corrected Volumetric Analysis as an Additive Endpoint in Phase I Solid Tumour Programs: Methodology and Early Clinical Experience
Topic / Theme
Developmental Therapeutics — Imaging and Biomarker Endpoints in Early-Phase Trials
Session
Tuesday 3 June — Poster Display Hall B, Board
Poster ID
TBC — to be confirmed by ASCO
Authors
- Roughan Sheedy: Managing Director, Fidēs Imaging
- Beth Fisher: Product Specialist, Fidēs Imaging
- Co-author TBC: External KOL, to be confirmed
RSNA 2026: Radiological Society of North America Annual Meeting
More from the Fidēs resource library.
Case Studies
Real programs, real imaging challenges and the scientific decisions behind them — across therapy areas and modalities.
View Case StudiesNews
Company updates, scientific commentary and announcements from the Fidēs team.
View NewsWhat we do
From study design through to final report — see how Fidēs supports every stage of the imaging lifecycle.
View Capabilities